A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular dystrophy, did not achieve its primary endpoint, according to findings published in Nature Medicine. A News and Views piece on the trial was published in the same journal issue.
$3.2 million per dose Elevidys fails to meet primary endpoint in phase 3 trial
Tech News
-
Free Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
Smart buildings: What happens to our free will when tech makes choices for us?
-
Screenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
Darknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
Privacy violations undermine the trustworthiness of the Tim Hortons brand
-
Why Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars